The Regulatory Data Gap Is Now a Competitive Moat — and Most Sponsors Are on the Wrong Side of It
Nature Reviews Drug Discovery's 2026 RWE framework signals a regulatory inflection point: sponsors who master data infrastructure will compress...
FDA Regulatory Strategy
Jupiter Neurosciences’ $100M ALA-002 Bet Is a Regulatory Arbitrage Play, Not a Science Story
Jupiter Neurosciences (JUNS) just licensed ALA-002, a Novel Chemical Entity MDMA, for $100M+—here's why the NCE status matters more...